<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-101687</identifier>
<setSpec>0004-0614</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Histological changes due to intravesical instillation of Mitomycin C</dc:title>
<dc:description xml:lang="en">OBJECTIVE: Transurethral resection (TUR) is highly effective in the local control of superficial bladder cancer. However, the recurrence rate can reach 80% of the cases. Adjuvant intravesical chemotherapy may decrease significantly tumor recurrence. We describe a bladder adverse reaction to mitomycin C as adjuvant therapy for non-invasive bladder cancer. METHODS: Three patients with diagnosis of pTa G1 urothelial carcinoma were treated by TUR plus an instillation of 40 mg. of mitomicin C. A month later, the patients were attended for dysuria and hematuria. Cystoscopy and bladder biopsy were performed in all cases.RESULTS: Multiple sessile lesions suspicious of tumor recurrence were found on cystoscopy. The histopathological diagnosis disclosed the existence of severe atypia of the urothelium and stromal changes similar to those observed after radiotherapy. CONCLUSIONS: Adjuvant intravesical chemotherapy with mitomycin C may cause local reactions with macroscopic patterns similar to tumoral recurrences(AU)</dc:description>
<dc:creator>Feria-Flores, Miguel</dc:creator>
<dc:creator>Castillo, Octavio A</dc:creator>
<dc:creator>Vidal-Mora, Ivar</dc:creator>
<dc:creator>Landerer, Eduardo</dc:creator>
<dc:creator>Franco, Carmen</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">OBJETIVO: La resección transuretral (RTU) es un tratamiento altamente eficiente en el control local del cáncer vesical superficial. Sin embargo, la tasa de recurrencia puede llegar al 80% de los casos. La quimioterapia intravesical adyuvante puede disminuir significativamente la recidiva tumoral. Este artículo describe una reacción adversa intravesical al uso de Mitomicina C como terapia adyuvante del cáncer vesical no invasor. MÉTODOS: Tres pacientes con el diagnóstico de un carcinoma de urotelio pTa G1, fueron tratados mediante RTU más una instilación vesical de 40 mg de Mitomicina C. Posteriormente, los pacientes consultaron por síndrome disúrico y hematuria. Se realizó una cistoscopía más biopsia vesical. RESULTADOS: Como hallazgo cistoscópico se encontraron múltiples lesiones sésiles cuyo informe biópsico descartó la presencia de tumor CONCLUSIÓN: La quimioterapia adyuvante intravesical con mitomicina C puede producir reacciones adversas endoluminales con patrones macroscópicos similares a los de una recidiva tumoral(AU)</dc:description>
<dc:source>Arch Esp Urol;65(5): 578-582, jun. 2012. ilus</dc:source>
<dc:identifier>ibc-101687</dc:identifier>
<dc:title xml:lang="es">Cambios histológicos provocados por la instilación intravesical de mitomicina C</dc:title>
<dc:subject>^d30853</dc:subject>
<dc:subject>^d3576^s22045</dc:subject>
<dc:subject>^d36513^s22053</dc:subject>
<dc:subject>^d3576^s22066</dc:subject>
<dc:subject>^d36513^s22021</dc:subject>
<dc:subject>^d32875^s22021</dc:subject>
<dc:subject>^d3576^s22074</dc:subject>
<dc:subject>^d32875^s22053</dc:subject>
<dc:subject>^d1731^s22074</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d1774^s22057</dc:subject>
<dc:subject>^d29961^s22020</dc:subject>
<dc:subject>^d21044</dc:subject>
<dc:subject>^d32875^s29166</dc:subject>
<dc:subject>^d1731^s22045</dc:subject>
<dc:type>article</dc:type>
<dc:date>201206</dc:date>
</metadata>
</record>
</ibecs-document>
